- Home
- BCDA vs CMND Comparison
BCDA vs CMND Comparison
Compare BCDA & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- CMND
- Stock Information
- Founded
- BCDA N/A
- CMND 2017
- Country
- BCDA United States
- CMND Canada
- Employees
- BCDA N/A
- CMND N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- CMND Health Care
- Exchange
- BCDA Nasdaq
- CMND Nasdaq
- Market Cap
- BCDA 7.9M
- CMND 7.5M
- IPO Year
- BCDA N/A
- CMND N/A
- Fundamental
- Price
- BCDA $2.18
- CMND $1.49
- Analyst Decision
- BCDA Strong Buy
- CMND
- Analyst Count
- BCDA 1
- CMND 0
- Target Price
- BCDA $25.00
- CMND N/A
- AVG Volume (30 Days)
- BCDA 52.4K
- CMND 2.9M
- Earning Date
- BCDA 11-13-2024
- CMND 01-28-2025
- Dividend Yield
- BCDA N/A
- CMND N/A
- EPS Growth
- BCDA N/A
- CMND N/A
- EPS
- BCDA N/A
- CMND N/A
- Revenue
- BCDA $71,000.00
- CMND N/A
- Revenue This Year
- BCDA N/A
- CMND N/A
- Revenue Next Year
- BCDA N/A
- CMND N/A
- P/E Ratio
- BCDA N/A
- CMND N/A
- Revenue Growth
- BCDA N/A
- CMND N/A
- 52 Week Low
- BCDA $1.63
- CMND $0.92
- 52 Week High
- BCDA $8.85
- CMND $2.30
- Technical
- Relative Strength Index (RSI)
- BCDA 49.10
- CMND 52.63
- Support Level
- BCDA $2.05
- CMND $1.41
- Resistance Level
- BCDA $2.36
- CMND $1.62
- Average True Range (ATR)
- BCDA 0.21
- CMND 0.13
- MACD
- BCDA -0.00
- CMND 0.00
- Stochastic Oscillator
- BCDA 46.43
- CMND 33.33
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.